--- title: "Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $1,862,600.00 in Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/292183442.md" description: "Corcept Therapeutics insider William Guyer sold 20,000 shares for $1.86 million on July 7, reducing his stake by 83.39%. This follows similar sales in May and June. Meanwhile, institutional investors like JPMorgan and Allspring increased their holdings significantly in recent quarters. Analysts maintain a 'Moderate Buy' consensus with an average price target of $88.83." datetime: "2026-07-09T10:22:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292183442.md) - [en](https://longbridge.com/en/news/292183442.md) - [zh-HK](https://longbridge.com/zh-HK/news/292183442.md) --- # Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $1,862,600.00 in Stock Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider William Guyer sold 20,000 shares of the business's stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $93.13, for a total value of $1,862,600.00. Following the completion of the transaction, the insider directly owned 3,985 shares of the company's stock, valued at approximately $371,123.05. This trade represents a 83.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. - 3 Biopharmaceutical Stocks Bucking the Sell-Off William Guyer also recently made the following trade(s): - On Tuesday, June 2nd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $70.60, for a total value of $1,412,000.00. - On Tuesday, May 5th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $51.83, for a total value of $1,036,600.00. ## Corcept Therapeutics Trading Down 1.2% Shares of CORT stock opened at $92.94 on Thursday. The stock has a 50 day moving average of $70.78 and a 200 day moving average of $52.44. The stock has a market cap of $9.98 billion, a P/E ratio of 265.55 and a beta of 0.47. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $94.77. * * * * * * Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The company had revenue of $164.90 million during the quarter, compared to analyst estimates of $185.83 million. During the same period in the previous year, the firm posted $0.17 earnings per share. The company's revenue was up 4.9% compared to the same quarter last year. On average, research analysts predict that Corcept Therapeutics Incorporated will post 0.53 earnings per share for the current fiscal year. ## Wall Street Analysts Forecast Growth CORT has been the topic of a number of recent analyst reports. Zacks Research raised shares of Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, May 4th. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $110.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, May 28th. HC Wainwright upped their price objective on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the stock a "buy" rating in a research report on Tuesday, June 2nd. Weiss Ratings reissued a "hold (c-)" rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Finally, UBS Group set a $135.00 target price on shares of Corcept Therapeutics in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $88.83. **Read Our Latest Report on CORT** ## Institutional Inflows and Outflows Several large investors have recently made changes to their positions in CORT. JPMorgan Chase & Co. increased its holdings in Corcept Therapeutics by 223.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company's stock worth $70,632,000 after acquiring an additional 587,053 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Corcept Therapeutics by 111.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 507,967 shares of the biotechnology company's stock valued at $19,404,000 after purchasing an additional 268,155 shares in the last quarter. First Trust Advisors LP lifted its holdings in Corcept Therapeutics by 34.1% during the third quarter. First Trust Advisors LP now owns 720,224 shares of the biotechnology company's stock valued at $59,858,000 after purchasing an additional 183,038 shares in the last quarter. Checkpoint Capital L.P. grew its position in shares of Corcept Therapeutics by 14.1% in the third quarter. Checkpoint Capital L.P. now owns 392,331 shares of the biotechnology company's stock valued at $32,607,000 after purchasing an additional 48,414 shares during the period. Finally, Avidity Partners Management LP acquired a new stake in shares of Corcept Therapeutics in the fourth quarter valued at about $766,000. 93.61% of the stock is owned by institutional investors and hedge funds. ## About Corcept Therapeutics (Get Free Report) Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs. The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. ## Further Reading - Five stocks we like better than Corcept Therapeutics - A Market Panic Just Discounted the AI Highway's Tollbooth - Why Exxon Could Be the Market's Next Big Comeback Stock - The Market Just Got Shaken—These 3 ETFs May Come Out Stronger - Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns _This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\]._ Insider Buying or Selling at Corcept Therapeutics? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Corcept Therapeutics and related companies. From Our Partners Trump's gold order: the announcement they won't put on the front page On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb... Reagan Gold Group The $15 Gold Fund That Pays Up to $1,152/Month Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying... Investors Alley Trump Takes Emergency Action - Plus Elon Musk's New Venture Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru... Altimetry Do NOT Buy SpaceX – Do This Instead SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul... Stansberry Research SPCX Warning - and Worst News for Stocks in 50 Years Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ... TradeSmith Your $29.97 book is free today Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca... Profits Run CODE RED: AI Meltdown Imminent? After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri... Paradigm Press Better than SpaceX? Grab this ticker instead. Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says... Brownstone Research ### Related Stocks - [CORT.US](https://longbridge.com/en/quote/CORT.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [JPMO.US](https://longbridge.com/en/quote/JPMO.US.md) - [JPX.US](https://longbridge.com/en/quote/JPX.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [Wolfe Research Reiterates "Underperform" Rating for Corcept Therapeutics (NASDAQ:CORT)](https://longbridge.com/en/news/293929462.md) - [Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know](https://longbridge.com/en/news/294319695.md) - [Corcept (CORT) Q2 Earnings: What To Expect](https://longbridge.com/en/news/294004716.md) - [Intuitive Surgical (NASDAQ:ISRG) EVP Sells $10,085.88 in Stock](https://longbridge.com/en/news/294272745.md) - [Insider Selling: ACRES Commercial Realty (NYSE:ACR) Major Shareholder Sells 1,389 Shares of Stock](https://longbridge.com/en/news/294282341.md)